The U.S. Food and Drug Administration has approved Johnson & Johnson’s (J&J) TREMFYA (guselkumab) for children aged six years and older weighing at least 40 kg with moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA). This marks the first approval of an IL-23 inhibitor for these pediatric indications, expanding the drug’s use beyond its prior approvals for adults with moderate to severe plaque PsO in 2017 and active PsA in 2020. The approval addresses a si...